阅读说明：本技术 肉苁蓉苯乙醇苷在制备治疗心肌肥厚药物中的应用 (Application of cistanche phenylethanoid glycosides in preparation of medicine for treating myocardial hypertrophy ) 是由 由淑萍 樊琼玲 刘涛 赵军 王家威 马龙 于 2019-11-26 设计创作，主要内容包括：本发明公开了一种肉苁蓉苯乙醇苷类提取物在制备治疗心肌肥厚药物中的应用,利用腹主动脉缩窄术建立大鼠心肌肥厚模型,应用不同剂量的中药肉苁蓉提取物,选取缬沙坦为阳性对照药,经药效学整体动物实验研究,取得了肯定的疗效,并且为心肌肥厚治疗药物的筛选提供了依据。(The invention discloses an application of cistanche phenylethanoid glycosides extracts in preparing a medicament for treating cardiac hypertrophy, wherein a rat cardiac hypertrophy model is established by abdominal aortic coarctation, different doses of traditional Chinese medicine cistanche extracts are applied, valsartan is selected as a positive control medicament, and a positive curative effect is obtained through pharmacodynamic whole animal experiment research, and a basis is provided for screening of the medicament for treating cardiac hypertrophy.)

1. Application of cistanche phenylethanoid glycosides in preparing medicine for treating myocardial hypertrophy is provided.

2. The use of the cistanche phenylethanoid glycosides in the preparation of a medicament for the treatment of myocardial hypertrophy as claimed in claim 1, wherein the cistanche phenylethanoid glycosides extract is capable of decreasing LVPWT and increasing LVEDD, LVEF and LVFS of the heart.

3. The use of the cistanche phenylethanoid glycosides in the preparation of a medicament for the treatment of myocardial hypertrophy as claimed in claim 1, wherein the cistanche phenylethanoid glycosides extract is capable of lowering the body heart weight index.

4. The use of the cistanche phenylethanoid glycosides in the preparation of a medicament for the treatment of myocardial hypertrophy as claimed in claim 1, wherein the cistanche phenylethanoid glycosides extract is capable of lowering the levels of BNP and ET-1 in plasma.

5. The use of the cistanche phenylethanoid glycosides in the manufacture of a medicament for the treatment of myocardial hypertrophy as claimed in claim 1 wherein the cistanche phenylethanoid glycoside extract is capable of lowering the levels of ANP and β -MHC in the myocardial tissue.

Technical Field

The invention relates to the technical field of biomedicine, in particular to application of cistanche phenylethanoid glycosides in preparation of a medicine for treating myocardial hypertrophy.

Background

Myocardial hypertrophy, an independent risk factor for a variety of cardiovascular diseases, is considered a compensatory mechanism in the pre-hypertensive phase by increasing ventricular wall tension to accommodate pressure overload and elevated blood pressure; as myocardial hypertrophy increases, myocardial blood supply needs increase, and coronary flow reserves decrease resulting in myocardial damage, leading to increased morbidity and mortality from cardiovascular disease. Diuretics, calcium channel blockers, renin-angiotensin system inhibitors and the like are commonly used in medicine as main clinical drugs for treating hypertension and myocardial hypertrophy. However, adverse reactions such as electrolyte disturbance, postural hypotension, dry cough and the like caused by taking the medicines are not negligible. Therefore, the search for a high-efficiency and low-toxic-side-effect medicament, and the prevention, reversal and treatment of hypertension myocardial hypertrophy are the main problems of the current research.

Cistanche salsa is a parasitic plant parasitic on the root of haloxylon ammodendron in desert trees, and absorbs nutrients and water from haloxylon ammodendron hosts. Cistanche deserticola (Cistance) has reputation of desert ginseng, has extremely high medicinal value and is a traditional famous and precious Chinese traditional medicine. Cistanche phenylethanoid glycosides (CPhgs) are one of the main material bases of cistanche for playing drug effects, and the main components of the cistanche phenylethanoid glycosides are echinacoside and acteoside. In recent years, cistanche has attracted attention by people with remarkable biological activity, wherein the special functional effects of cistanche in nourishing liver and kidney, regulating nucleic acid metabolism of animals with yang deficiency and yin deficiency and promoting deoxyribonucleic acid synthesis are matched with syndrome differentiation of hypertension traditional Chinese medicine.

Researches show that CPhGs can relieve the damage of free radicals to myocardial mitochondrial membranes and seroomentum, reduce the content of MDA, relieve the damage of myocardial ultrastructure, improve the antioxidant enzyme activity of rat myocardial mitochondria, reduce myocardial infarction area, improve the phosphocreatine kinase activity of myocardial tissues and have a protective effect on ischemic myocardium, but at present, it is unknown whether CPhGs can prevent and treat myocardial hypertrophy.

Therefore, the problem that how to determine the specific medicinal mechanism of the cistanche phenylethanoid glycosides and apply the cistanche phenylethanoid glycosides to the medicine for treating myocardial hypertrophy needs to be solved urgently by the technical personnel in the field.

Disclosure of Invention

In view of the above, the invention establishes a rat myocardial hypertrophy model by abdominal aortic coarctation, uses the traditional Chinese medicine cistanche extracts with different doses, selects valsartan as a positive control drug, obtains a positive curative effect through pharmacodynamics whole animal experiment research, and provides a basis for screening myocardial hypertrophy treatment drugs.

In order to achieve the purpose, the invention adopts the following technical scheme:

application of cistanche phenylethanoid glycosides in preparing medicine for treating myocardial hypertrophy is provided.

The technical effect achieved by the technical scheme is as follows: the cistanche phenylethanoid glycoside extract is extracted from cistanche, and researches show that the cistanche phenylethanoid glycoside extract can effectively prevent, relieve and treat hypertension myocardial hypertrophy, has low toxic and side effects, is convenient for further developing and applying the effects of the cistanche phenylethanoid glycoside extract, and brings good news to patients with hypertension myocardial hypertrophy.

As the preferred technical scheme of the invention, the cistanche phenylethanoid glycosides can reduce LVPWT of the heart and increase LVEDD, LVEF and LVFS of the heart.

As the preferred technical scheme of the invention, the cistanche phenylethanoid glycosides can reduce the heart weight index of organisms.

As the preferred technical scheme of the invention, the cistanche phenylethanoid glycosides can reduce the BNP and ET-1 levels in blood plasma.

As a preferred technical scheme of the invention, the cistanche phenylethanoid glycosides can reduce the levels of ANP and β -MHC in myocardial tissues.

According to the technical scheme, compared with the prior art, the invention discloses the application of the cistanche phenylethanoid glycosides in preparing the medicine for treating the myocardial hypertrophy, and the concrete relation of the cistanche phenylethanoid glycosides to the myocardial hypertrophy is discussed through establishing a rat myocardial hypertrophy model, and the concrete action mechanism of the cistanche phenylethanoid glycosides is obtained (namely, the LVEDD, LVEF and LVFS of the heart are increased by reducing the LVPWT of the heart, the heart weight index of an organism is reduced, the BNP and ET-1 levels in blood plasma are reduced, and the ANP and β -MHC levels in myocardial tissues are reduced).

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.

FIG. 1 is a pathological diagram of myocardial tissues of mice of each group in example 6;

FIG. 2 is a graph showing the myocardial area characterization of the groups of mice in example 6;

FIG. 3 is a graph showing the expression levels of cardiac hypertrophy genes ANP and β -MHC in example 7 measured by qRT-PCR.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.